Search Results - "Ronchi, C L"

Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells by Peverelli, E., Catalano, R., Giardino, E., Treppiedi, D., Morelli, V., Ronchi, C.L., Vaczlavik, A., Fusco, N., Ferrero, S., Bertherat, J., Beuschlein, F., Chiodini, I., Arosio, M., Spada, A., Mantovani, G.

“…cAMP pathway plays a major role in the pathogenesis of cortisol-producing adrenocortical adenomas (CPA). cAMP-induced steroidogenesis is preceded by actin…”
Get full text

Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments by Ronchi, C L, Giavoli, C, Ferrante, E, Verrua, E, Bergamaschi, S, Ferrari, D I, Corbetta, S, Montefusco, L, Arosio, M, Ambrosi, B, Spada, A, Beck-Peccoz, P

“…ObjectiveRadiotherapy (RT) for pituitary adenomas, including GH-secreting ones, frequently leads to GH deficiency (GHD). Data on the effects of surgery alone…”
Get full text

GH Response to Oral Glucose Tolerance Test: A Comparison between Patients with Acromegaly and Other Pituitary Disorders by Verrua, E, Filopanti, M, Ronchi, C. L, Olgiati, L, Ferrante, E, Giavoli, C, Sala, E, Mantovani, G, Arosio, M, Beck-Peccoz, P, Lania, A. G, Spada, A

“…Context: The cutoff value of nadir GH after an oral glucose tolerance test (OGTT) used to define disease remission in acromegaly is higher than that observed…”
Get full text

Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients by Peverelli, E, Ermetici, F, Filopanti, M, Elli, F M, Ronchi, C L, Mantovani, G, Ferrero, S, Bosari, S, Beck-Peccoz, P, Lania, A, Spada, A

“…ObjectivesAberrant cAMP signaling is involved in the pathogenesis of somatotropinomas. The aim of the study was to screen acromegalic patients for the presence…”
Get full text

S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study by Elhassan, Y S, Altieri, B, Berhane, S, Cosentini, D, Calabrese, A, Haissaguerre, M, Kastelan, D, Fragoso, M C B V, Bertherat, J, Al Ghuzlan, A, Haak, H, Boudina, M, Canu, L, Loli, P, Sherlock, M, Kimpel, O, Laganà, M, Sitch, A J, Kroiss, M, Arlt, W, Terzolo, M, Berruti, A, Deeks, J J, Libé, R, Fassnacht, M, Ronchi, C L

“…Objective Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course. Prognostic stratification based on the European Network for the Study…”
Get full text

Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study by Libé, R., Borget, I., Ronchi, C.L., Zaggia, B., Kroiss, M., Kerkhofs, T., Bertherat, J., Volante, M., Quinkler, M., Chabre, O., Bala, M., Tabarin, A., Beuschlein, F., Vezzosi, D., Deutschbein, T., Borson-Chazot, F., Hermsen, I., Stell, A., Fottner, C., Leboulleux, S., Hahner, S., Mannelli, M., Berruti, A., Haak, H., Terzolo, M., Fassnacht, M., Baudin, E.

“…The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic…”
Get full text

Inflammation-based scores in a large cohort of adrenocortical carcinoma and adrenocortical adenoma: role of the hormonal secretion pattern by Mangone, A, Favero, V, Prete, A, Elhassan, Y S, Asia, M, Hardy, R, Mantovani, G, Chiodini, I, Ronchi, C L

“…Serum inflammation-based scores can predict clinical outcome in several cancer types, including adrenocortical carcinoma (ACC). It is unclear whether the…”
Get full text

GH Response to Oral Glucose Tolerance Test: A Comparison between Patients with Acromegaly and Other Pituitary Disorders by Verrua, E, Filopanti, M, Ronchi, C. L, Olgiati, L, Ferrante, E, Giavoli, C, Sala, E, Mantovani, G, Arosio, M, Beck-Peccoz, P, Lania, A. G, Spada, A

“…J Clin Endocrinol Metab, published October 20, 2010, 10.1210/jc.2010-1115…”
Get full text

GH Response to Oral Glucose Tolerance Test: A Comparison between Patients with Acromegaly and Other Pituitary Disorders by Verrua, E, Filopanti, M, Ronchi, C. L, Olgiati, L, Ferrante, E, Giavoli, C, Sala, E, Mantovani, G, Arosio, M, Beck-Peccoz, P, Lania, A. G, Spada, A

“…J Clin Endocrinol Metab, published October 20, 2010, 10.1210/jc.2010-1115…”
Get full text

Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients by Ronchi, C. L., Ferrante, E., Rizzo, E., Giavoli, C., Verrua, E., Bergamaschi, S., Lania, A.G., Beck-Peccoz, P., Spada†, A.

“…Summary Objective  Long‐term effects of trans‐naso‐sphenoidal surgery (TNS) or long‐acting somatostatin analogs (SSA) on the function of…”
Get full text

Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients by RONCHI, C. L, CORBETTA, S, CAPPIELLO, V, MORPURGO, P. S, GIAVOLI, C, BECK-PECCOZ, P, AROSIO, M, SPADA, A

“…Adiponectin (ApN) is an adipocytokine expressed in human adipose cells with anti-atherogenic and anti-inflammatory properties that plays a role in the…”
Get full text

An unusual case of recurrent autoimmune hypophysitis by Giavoli, C, Ferrante, E, Bergamaschi, S, Ronchi, C L, Lania, A G, Spada, A, Beck-Peccoz, P

“…Autoimmune hypophysitis (AH) is an inflammatory disease that can present either as empty sella or as pituitary mass. A 16-years-old girl was admitted at our…”
Get more information

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience by Sala, E., Carosi, G., Del Sindaco, G., Mungari, R., Cremaschi, A., Serban, A. L., Ronchi, C. L., Ferrante, E., Arosio, M., Mantovani, G.

“…Purpose A long-lasting remission of acromegaly after somatostatin analogues (SAs) withdrawal has been described in some series. Our aim was to update the…”
Get full text

Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma by Verrua, E, Ronchi, C. L, Ferrante, E, Ferrari, D. I, Bergamaschi, S, Ferrero, S, Zatelli, M. C, Branca, V, Spada, A, Beck-Peccoz, P, Lania, A. G

“…In this report we emphasize the opportunity of considering the uncommon causes of chronic GH-excess in the initial diagnostic process, such as GHRH…”
Get full text

Ghrelin administration affects circulating pituitary and gastro-entero-pancreatic hormones in acromegaly by Arosio, M, Ronchi, CL, Gebbia, C, Pizzinelli, S, Conte, D, Cappiello, V, Epaminonda, P, Cesana, BM, Beck-Peccoz, P, Peracchi, M

“…OBJECTIVE: Ghrelin, a gut-brain peptide involved in the control of energy homeostasis, affects antero-pituitary and gastro-entero-pancreatic (GEP) hormone…”
Get full text

The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study by Creemers, S G, Feelders, R A, Valdes, N, Ronchi, C L, Volante, M, van Hemel, B M, Luconi, M, Ettaieb, M H T, Mannelli, M, Chiara, M D, Fassnacht, M, Papotti, M, Kerstens, M N, Nesi, G, Haak, H R, van Kemenade, F J, Hofland, L J

“…Adrenocortical carcinoma (ACC) is diagnosed using the histopathological Weiss score (WS), but remains clinically elusive unless it has metastasized or grows…”
Get full text

Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues by RONCHI, C. L, ORSI, E, GIAVOLI, C, CAPPIELLO, V, EPAMINONDA, P, BECK-PECCOZ, P, AROSIO, M

“…Many studies have recently shown that simple computer-solved indices, based on fasting glucose and insulin levels, closely mirror the euglycemic clamp…”
Get full text

Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study by Ronchi, C L, Boschetti, M, Degli Uberti, E C, Mariotti, S, Grottoli, S, Loli, P, Lombardi, G, Tamburrano, G, Arvigo, M, Angeletti, G, Boscani, P F, Beck-Peccoz, P, Arosio, M

“…Lanreotide Autogel 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high-dose, sustained-release aqueous gel formulation, supplied in a prefilled syringe and…”
Get full text

Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study by Ronchi, C. L., Boschetti, M., Uberti, E. C. Degli, Mariotti, S., Grottoli, S., Loli, P., Lombardi, G., Tamburrano, G., Arvigo, M., Angeletti, G., Boscani, P. F., Beck-Peccoz, P., Arosio, M.

“…Summary Objective   Lanreotide Autogel® 120 mg (ATG120; Ipsen S.p.A, Milan, Italy) is a high‐dose, sustained‐release aqueous gel formulation, supplied in a…”
Get full text

Growth hormone therapy in GH-deficient adults: continuous vs alternate-days treatment by Giavoli, C, Cappiello, V, Porretti, S, Ronchi, C L, Orsi, E, Beck-Peccoz, P, Arosio, M

“…In the present report, we have compared 12 months of rhGH therapy given daily (D) at the beginning and then on alternate days (A) to 20 subjects with severe…”
Get more information